VBCN - November 2016 Volume 3, No 3

Despite improvements in radiographic diagnostic techniques, including magnetic resonance imaging (MRI), the misdiagnosis of multiple sclerosis (MS) is a common problem that can lead to treatment-related and psychosocial morbidity.
Read More

Recent advances in brain–computer interfaces have moved these devices closer than ever to daily use, offering hope to millions of patients suffering from neurologic disability, said Karunesh Ganguly, MD, PhD, Assistant Professor of Neurology, University of California, San Francisco, at the 2016 American Academy of Neurology annual meeting.
Read More

“Of course, the Holy Grail of pain treatment would be to treat the affected site directly,” said Max M. Klein, PhD, Instructor of Neurology, Massachusetts General Hospital, Boston, at the 2016 American Academy of Pain Medicine meeting.
Read More

An often overlooked condition, central neuropathic pain ensues directly when any type of central nervous system (CNS) lesion causes the dysfunction of somatosensory CNS pathways. It occurs most often after a stroke or as sequelae of multiple sclerosis or spinal cord injury, explained James C. Watson, MD, Associate Professor of Neurology, Mayo Clinic, Rochester, MN, at the 2016 American Academy of Pain Medicine meeting. Central neuropathic pain is challenging to diagnose and treat.
Read More

Patients with early- versus late-onset epilepsy exhibited distinct differences in the origin of memory deficits, supporting the practice of subtyping patients by clinical characteristics to identify individualized predictors of cognitive dysfunction, according to the results of a new study.
Read More

Findings from an ongoing, phase 3 clinical trial involving patients with relapsing-remitting multiple sclerosis (MS) reveal that hematopoietic stem-cell transplantation (HSCT) may be a feasible treatment option for reversing disability associated with MS.
Read More

  • Sleep Disturbances Lead to Cognitive Decline
  • Alemtuzumab Demonstrates Superior Outcomes versus Interferon-ß-1a in Relapsing-Remitting Multiple Sclerosis
  • Aprepitant Relieves Nausea Associated with Dihydroergotamine Use for Migraine
  • Positive Effect of Hormone Therapy on Physical Function in Postmenopausal Women with Multiple Sclerosis
Read More

The past 2 decades have seen significant improvements in disease-modifying therapies (DMTs) for multiple sclerosis (MS), and with them a surge in prices in the cost of therapy with sales more than doubling just in the past few years. As a result, there has been a significant rise in the cost of care for patients with MS.
Read More

  • Abuse-Deterrent Troxyca ER Approved for Chronic Pain
Read More

Despite a dramatic increase in the use of thrombolytic therapy for acute ischemic stroke, 25% of eligible patients still do not receive this treatment, according to data from a national registry.
Read More

Page 1 of 2

Subscribe to Value-Based Care in Neurology

Stay up to date with the latest news in neurology by subscribing to receive the free VBCN e‑Newsletter.